University of Cairo Reports Findings in Doxorubicin Therapy (Mesoporous silica coated gold nanorods loaded doxorubicin for combined chemo-photothermal therapy)
By a News Reporter-Staff News Editor at Biotech Week -- New research on Drugs and Therapies is the subject of a report. According to news reporting originating from Giza, Egypt, by NewsRx correspondents, research stated, "The efficacy of the combined chemo-photothermal therapy, using a mesoporous silica-coated gold nanorods loaded DOX (pGNRs@mSiO(2)-DOX), was consistently tested both in vitro and in vivo. The prepared nanoparticles that were characterized using transmission electron microscopy (TEM), UV-vis absorption spectroscopy and zeta potential showed high doxorubicin loading capacity in addition to its pH-responsive release."
Our news editors obtained a quote from the research from the University of Cairo, "The pGNRs@mSiO(2)-DOX photo-heat conversion characteristic found to be stable for several repeated NIR irradiated doses was tested in simulated body fluid. In vitro results showed that pGNRs@mSiO(2)-DOX causes a significant damage in breast cancer cell line MCF-7 compared to free DOX. Contrary to this, it showed low toxicity to human amnion wish cells compared to CTAB coated GNRs and free DOX. In vivo results showed that intravenous administration of pGNRs@mSiO(2)-DOX (1.7 mg/kg) markedly suppresses the growth of subcutaneous Ehrlich carcinoma in female Balb mice (p
According to the news editors, the research concluded: "Based on the obtained results, this passively targeted pGNRs@mSiO(2)-DOX could specifically deliver drug and excessive local heat to tumor sites achieving high combined therapeutic efficacy."
For more information on this research see: Mesoporous silica coated gold nanorods loaded doxorubicin for combined chemo-photothermal therapy. International Journal of Pharmaceutics, 2014;470(1-2):1-7. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news editors report that additional information may be obtained by contacting A.S. Monem, Cairo University, Fac Sci, Dept. of Biophys, Giza 12613, Egypt. Additional authors for this research include N. Elbialy and N. Mohamed (see also Drugs and Therapies).
Keywords for this news article include: Giza, Antibiotics - Antineoplastics, Pharmaceuticals, Egypt, Africa, Drugs and Therapies, Doxorubicin Hydrochloride
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC